On health effects of resveratrol in wine.

1

2	A bibliometric view based on papers having achieved a high citation impact
3	within the scientific discourse
4	
5	Robin Haunschild and Werner Marx
6	Max Planck Institute for Solid State Research, Heisenbergstr. 1, 70569 Stuttgart (Germany)
7	R.Haunschild@fkf.mpg.de, W.Marx@fkf.mpg.de
8	
9	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

10

25

26

27

11 We analyzed 3344 publications that are concerned with the health-related effects of resveratrol that occurs in wine and grapes. We found that the publication activity increased 12 13 until 2010 and decreased slightly afterwards. The most frequent author keywords were classified into six groups: (1) beverages-related keywords, (2) compounds-related keywords, 14 (3) diseases-related keywords, (4) effects-related keywords, (5) mechanisms-related 15 16 keywords, and (6) broader keywords. By means of reference publication year spectroscopy, we analyzed and discussed the most frequently cited references (i.e., key papers) within the 17 publication set. A rather large portion of the key papers takes a positive attitude and reports 18 about health effects of resveratrol, although limited data in humans preclude drawing 19 20 unambiguous conclusions on the health-related benefits of resveratrol. From our analysis, we could not identify specific publications that provide a distinct change of direction of the 21 22 ongoing scientific discourse. Moderate red wine consumption seems to have the potential of being health promoting, whereas excessive alcohol consumption can induce liver cirrhosis 23 and cancer. 24

Keywords: scientometrics; bibliometric analysis; resveratrol; red wine; health effects; RPYS

# 1. Introduction

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

Wine is a complex beverage, containing a wide range of polyphenols, which represent the main class of bioactive compounds. Polyphenols are considered to effect health by preventing atherosclerosis and coronary heart disease (CHD) and are seen as potential cancer chemopreventive agents. The content and profile of polyphenols depend on variety, geographical origin, growing methods, and vinification processes. Red wines usually contain an order of magnitude more polyphenols than white wines (1). Among the broad compound class of polyphenols, resveratrol and its derivatives play a major role. Resveratrol (trans-3,5,4'trihydoxystilbene) was first isolated in 1939/40 by Michio Takaoka (2, 3) as a constituent of the roots of the medical plant white hellebore (Veratrum grandiflorum). We use the terms resveratrol and *trans*-resveratrol interchangeably. Since about 1990, the possible benefits of moderate consumption of red wine in the prevention of cancer and heart diseases have received increasing attention in the scientific community and in the popular media as well. The cardioprotective effects and the ability to suppress the proliferation of a wide variety of tumor cells made resveratrol a promising drug in human medicine. According to Wu, Wang (4), such attention has been prompted by research findings in the 1980s, supporting a relationship between red wine consumption and the French paradox: Although the French diet was richer in saturated fats and the concentration of plasma cholesterol was much higher, the mortality from cardiovascular disease was comparatively low. The high consumption of red wine during the meals was suggested as a possible explanation. This issue is still a topic in the scientific discussions. Until now, there is only one bibliometric analysis dealing with the newly emerging research topic about possible health effects of polyphenols and in particular of resveratrol in red wines (1). This paper provides a comprehensive overview of the relevant literature with regard to the

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

contributing authors, the origin of the major contributors and their institutions, the type of papers, and the research themes. However, the study does not present an in-depth analysis based on citation (impact) data, although a time curve of the overall citations of the publication set analyzed is presented. It would be interesting for many people to get to know the current status of the discourse: Is there convincing evidence for health effects of resveratrol and particularly of moderate red wine consumption? What do the in vivo studies based on humans reveal? Which kind of research should be supported further to get a clearer picture? We assume that the publications of the experts dealing with this research topic, which were most frequently cited within the research community, can deliver some interesting information. However, an ordinary citation ranking is by far not sufficient. We need to compare the citation impact of each paper with similar papers (i.e., papers of the same research topic and publication year). This study aims to reveal the key papers of the scientific discourse about the relationship between resveratrol as a specific polyphenol in wine and health effects, based on an analysis of the most-cited papers (cited references) within a carefully selected publication set. This approach of citation analysis is based on what Galton at the beginning of the 20th century called the wisdom of crowds (5). Citations measure the scientific impact of publications, which is one aspect of scientific quality. Revealing the key papers using citation analysis might deliver some information about the evolution of the scientific discourse. In consideration of the complexity of the underlying biochemistry and medicine, there is no easy path to get a valid picture of the current status of the knowledge. In this study, we try to answer the following question using well-proofed bibliometric methods: What are the main topics and the research results of the papers, which are referenced (cited) most-often within the relevant literature of the scientific community?

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

A bibliometric method called Reference Publication Year Spectroscopy (RPYS) (Marx, Bornmann, & Barth, 2013; Marx, Bornmann, Barth, & Leydesdorff, 2014) has been particularly developed to reveal the historical roots or origins of research fields. However, this method can also be used to identify the key papers within the continuing scientific discourse within such fields or topics. RPYS changes the perspective of citation analysis from a times cited to a cited reference analysis (6) and assumes that researchers produce a useful data output by the references cited in their publications. These references can be analyzed statistically with regard to the publications most relevant for their specific field of research. Whereas single scientists judge the origins of their research field more or less subjectively, the overall community might deliver a more objective picture (7). Researchers active in the field effectively "vote" by their cited references, to identify the publications most important for the evolution of their research field. This novel approach may at least partially avoid some of the subjectivity associated with the comparative evaluations of individual research studies in narrative reviews, now increasingly considered as a significant flaw within the peer review system. RPYS utilizes the following observation: analysis of the publication years of the references cited by all papers in a specific research field (i.e., analysis of the reference publication years, RPYs) shows that early RPYs are not equally represented. Some RPYs occur more frequently among the cited references than others. These RPYs appear as more or less pronounced peaks in the distribution of the RPYs (i.e., the RPY spectrogram). The peaks are frequently based on single or few publications, which have been referenced comparatively often compared to other publications of the relevant research community. These publications are of special significance to the analyzed research field.

This study aims to reveal those papers that have been cited comparatively often within the scientific discourse on health effects of the specific polyphenol resveratrol in wine. These key papers are analyzed further with regard to their topics and conclusions.

# 2. Dataset and Methods

#### 2.1 Dataset

The topic of our research includes different disciplines (e.g., chemistry, medicine, biology, and life sciences). Therefore, we used the multidisciplinary database Web of Science (WoS; 8) for this study. In WoS, we used the following search query to find publications related to resveratrol (probably also its derivatives) and wine: TS=(Resveratrol\* SAME (Wine\* OR Vin\* OR Grap\* OR Vitis\*)). By this we searched for "resveratrol" and the wine synonyms in the title, abstract, and keywords of publications. The operator SAME ensures that the term resveratrol and any of the wine synonyms is found in the same topic field (e.g., both terms occur in the title, or both terms occur in one of the other two topic fields).

We analyzed the WoS subject categories within the result set to find health-related ones. We used those health-related WoS subject categories to combine them with our search query related to resveratrol and wine for obtaining our final WoS query that is included in supporting information S1. We retrieved 3344 papers on October 05, 2021.

### 2.2 Methods

We created co-occurrence maps of author keywords using VOSviewer (9). The distance between two nodes is determined by the co-occurrence frequency of the terms. The size of the nodes is dependent on the number of publications with a specific keyword. The nodes can be colored according to various characteristics (e.g., cluster assignments, average number of citations, or average publication year). We colored the nodes according to the average

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

publication years of the publications connected to them. We included author keywords if they occurred at least ten times. We imported all 3344 papers with 181,218 cited references into CRExplorer (https://crexplorer.net; 10, 11, 12). The distinct number of cited references amounts to 94,828. Up to 30 different citing publication years are occurring. We used the automatic algorithm for clustering equivalent cited references with volume and page activated and a Levenshtein threshold of 0.75. This enabled merging of 165 cited references. We removed 92,771 cited references that occurred less than ten times to sharpen the spectrogram and avoid noise. Thus, 1892 cited references remained for our analysis. The RPYS spectrogram was plotted using R (13) with the R package 'BibPlots' (14). In addition to the static RPYS plot in this paper, we produced an interactive RPYS graph using the R package 'dygraphs' (15). We analyzed the RPYS spectrogram regarding relevant peaks of the five-year median deviation. Tukey's fences (16) were used to support the identification of the most important peaks: Important peaks are flagged based on the interquartile range of the median deviations (17). If unflagged RPYs with a similar NCR value occur around flagged RPYs, those unflagged RPYs should also be investigated. In addition, cited references that were cited very frequently in many citing years (N TOP10>=15) were analyzed (18). Such very frequently cited references might not form pronounced peaks in the spectrogram. Thus, the N TOP10 indicator is important to consider for finding frequently cited references. We also investigated the 15 most-referenced cited references (referenced at least 200 times). 3. Results In this study, we included all document types in our analysis. The vast majority of publications belong to the document types 'article' (n=2735, 81.8%), 'review' (n=447, 13.4%), and 'proceedings paper' (n=131, 3.9%). Although some publications belong to more

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

than one document type, these three groups contain 3200 (95.7%) of our analyzed publication set. In the following, we present three different analyses of our dataset: (1) An annual publication profile is presented. (2) Frequently occurring author keywords are analyzed. (3) The references cited in the publication set are analyzed and discussed. 3.1 Annual publication profile Figure 1 shows the annual publication profile of papers that deal with resveratrol in connection with wine and health. The number of publications is overall increasing until 2010 and slightly decreases afterwards. Figure 1: Annual publication profile of papers that deal with resveratrol in connection with wine and health 3.2 Keyword analysis Figure 2 shows a semantic map of frequently occurring author keywords. Obvious synonyms (see Table S1 in supporting information S2) were grouped together. The nodes (i.e., keywords) are colored by the average publication year of the corresponding publications. Figure 2: Semantic map of author keywords; clear synonyms (see Table B1) were grouped together; an interactive version is available at: https://s.gwdg.de/Q2BKwg. For an overview of the thematic content of the publications dealing with health effects of resveratrol in wine, we categorized the keywords as follows: (1) Keywords related to

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

beverages containing resveratrol (e.g., studies that analyze the amount of resveratrol as a function of the wine variety, the geographical origin, and the vinification process). (2) Keywords related to specific chemical compounds, particularly to the biochemistry of polyphenols. (3) Keywords related to the possible prevention of specific diseases. (4) Keywords studying possible health effects of resveratrol in vitro or in vivo. (5) Keywords that are focused on the biochemical mechanism of a specific health effect, by which resveratrol possibly acts. We have assigned the keywords in Figure 2 to those topics and include a further category with unspecific or broader terms (each arranged in the order of occurrence): 1. Beverages related: wine (133), red wine (108), grapes (72), vitis vinifera (37), grape juice (22), grape seed extract (18), grapevine (13), vitis amurensis (12), vitaceae (12) 2. Compounds related: resveratrol (1531), polyphenols (306), stilbenes (90), nitric oxide (86), phenolics (57), flavonoids (56), reactive oxygen species (56), quercetin (54), alcohol (53), phytochemical (48), piceatannol (40), hplc (34), pterostilbene (34), curcumin (29), ethanol (26), egcg (21), cytokines (20), sirtuins (20), ampk (19), glutathione (16), phytoestrogen (15), red wine polyphenols (15), calcium (13), cytochrome p450 (13), stilbenoids (13), anthocyanins (12), caspase-3 (12), cholesterol (12), piceid (12), bcl-2 (11), catechin (11), cisplatin (11), cyclooxygenase (11), genistein (11), grape polyphenols (11), phytoalexin (11), superoxide dismutase (11), beta amyloid (10), doxorubicin (10), epsilon viniferin (10), hydrogen peroxide (10), lipopolysaccharide (10), melatonin (10), polydatin (10).polygonum cuspidatum (10) 3. Diseases related: atherosclerosis (63), cardiovascular disease (63), cancer (58), alzheimer's disease (46), diabetes (34), obesity (32), breast cancer (28), colon cancer (26), hypertension (25), liver (25), prostate cancer (23), diet (18), blood pressure (17), colorectal cancer (15), ischemia (15), metastasis (15), brain (14), heart (14), parkinson's disease (14), nf2 (13), hippocampus (12), ischemial/reperfusion (12),

187 cardiovascular (11), cerebral ischemia (11), neuroinflammation (11), microglia (10), neurodegeneration (10), osteoblast (10) 188 4. Effects related: apoptosis (240), oxidative stress (201), antioxidant (189), 189 inflammation (93), chemoprevention (68), neuroprotection (65), antioxidant activity 190 (51), rats (41), cardioprotection (24), mediterranean diet (24), nutraceutical (23), anti-191 inflammatory (20), invasion (16), antioxidant capacity (13), prevention (13), cancer 192 chemoprevention (12), clinical trials (12), health (12), anticancer (11), french paradox 193 194 (11), neuroinflammation (11), high-fat diet (10), insulin resistance (10) 5. Mechanisms related: cell cycle (39), sirt1 (55), nf-kappa b (38), angiogenesis (33), 195 cytotoxicity (33), mitochondria (32), bioavailability (31), autophagy (28), metabolism 196 197 (27), pharmacokinetics (27), endothelium (26), free radicals (26), p53 (25), lipid peroxidation (24), endothelial cells (22), platelets (16), gene expression (15), 198 molecular docking (15), endothelial function (14), platelet aggregation (14), tnf-alpha 199 (14), dna damage (13), macrophages (12), vegf (12), blood platelets (11), caco-2 cells 200 201 (10), endothelial dysfunction (10), estrogen receptor (10), inducible nitric oxide 202 synthase (10) 6. Broader terms: aging (41), proliferation (28), akt (21), cell proliferation (20), longevity 203 204 (12), migration (11), differentiation (10), natural products (10), ros (10), toxicity (10) 205 3.3 Reference analysis 206 Figure 3 shows the RPYS spectrogram of the wine- and health-related resveratrol research. 207 The grey bars show the number of cited references (NCR) in each year, and the blue line shows the five-year median deviation. Outlier peaks are indicated by red stars and marked 208 209 with their RPY.

Figure 3: RPYS spectrogram of the wine- and health-related resveratrol research; an interactive version is available at: <a href="https://s.gwdg.de/i4qfNZ">https://s.gwdg.de/i4qfNZ</a>.

Table 1 shows the most frequently cited references below the main peaks in Figure 3. Although 1939/1940 is not an outlier peak, we included CR1 and CR2 from these two years because they report about the first isolation of phenolic substances from the roots of the medical plant white hellebore (Veratrum grandiflorum). These CRs can be seen as the historical origin of research on resveratrol as a plant product.

Table 1: Most frequently cited references below the main peaks in Figure 3

#CR	Cited reference	RPY	NCR
1	Takaoka M., 1939, Nippon Kagaku Kaishi, V60, P1090, DOI	1939	12
	10.1246/nikkashi1921.60.1090		
2	Takaoka M.J., 1940, J. Fac. Sci. Hokkaido Imperi, V3, P1	1940	41
3	Langcake P., 1976, Physiol. Plant Pathol., V9, P77, DOI 10.1016/0048-	1976	149
	4059(76)90077-1		
4	Renaud S., 1992, Lancet, V339, P1523, DOI 10.1016/0140-	1992	459
	6736(92)91277-F		
5	Siemann E.H., 1992, Am. J. Enol. Viticult., V43, P49	1992	200
6	Frankel E.N., 1993, Lancet, V341, P1103, DOI 10.1016/0140-	1993	269
	6736(93)92472-6		
7	Frankel E.N., 1993, Lancet, V341, P454, DOI 10.1016/0140-	1993	120
	6736(93)90206-V		
8	Fitzpatrick D.F., 1993, Am. J. Physiol., V265, pH774	1993	87

9	Pace-Asciak C.R., 1995, Clin. Chim. Acta, V235, P207, DOI	1995	283
	10.1016/0009-8981(95)06045-1		
10	Bertelli A.A.E., 1995, Int. J. Tissue React., V17, P1	1995	166
11	Jang M.S., 1997, Science, V275, P218, DOI	1997	895
	10.1126/science.275.5297.218		
12	Gehm B.D., 1997, PNAS USA, V94, P14138, DOI	1997	289
	10.1073/pnas.94.25.14138		
13	Soleas G.J., 1997, Clin. Biochem., V30, P91, DOI 10.1016/S0009-	1997	233
	9120(96)00155-5		
14	Fremont L., 2000, Life Sci., V66, P663, DOI 10.1016/S0024-	2000	336
	3205(99)00410-5		
15	Manna S.K., 2000, J. Immunol., V164, P6509, DOI	2000	161
	10.4049/jimmunol.164.12.6509		
16	Hung L.M., 2000, Cardiovasc. Res., V47, P549, DOI 10.1016/S0008-	2000	141
	6363(00)00102-4		
17	Wallerath T., 2002, Circulation, V106, P1652, DOI	2002	189
	10.1161/01.CIR.0000029925.18593.5C		
18	Burns J., 2002, J. Agr. Food Chem., V50, P3337, DOI	2002	111
	10.1021/jf0112973		
19	Wang Q., 2002, Brain Res., V958, P439, DOI 10.1016/S0006-	2002	108
	8993(02)03543-6		
20	Baur J.A., 2006, Nat. Rev. Drug. Discov., V5, P493, DOI	2006	427
	10.1038/nrd2060		
21	Baur J.A., 2006, Nature, V444, P337, DOI 10.1038/nature05354	2006	302
22	Lagouge M., 2006, Cell, V127, P1109, DOI 10.1016/j.cell.2006.11.013	2006	197

23	Brown V.A., 2010, Cancer Res., V70, P9003, DOI 10.1158/0008-	2010	75
	5472.CAN-10-2364		
24	Cottart C.H., 2010, Mol. Nutr. Food Res., V54, P7, DOI	2010	66
	10.1002/mnfr.200900437		
25	Pacholec M., 2010, J. Biol. Chem., V285, P8340, DOI	2010	56
	10.1074/jbc.M109.088682		
26	Patel K.R., 2010, Cancer. Res., V70, P7392, DOI 10.1158/0008-	2010	55
	5472.CAN-10-2027		
27	Chow H.H.S., 2010, Cancer Prev. Res., V3, P1168, DOI 10.1158/1940-	2010	48
	6207.CAPR-09-0155		

220

221

222

223

224

225

226

227

228

229

230

231

232

233

In CR3, Langcake and Pryce reported the detection of trans-resveratrol in vitis vinifera and other vitaceaes as a response to infection and injury. In CR4, Renaud and Delorgeril discussed the so-called French paradox for coronary heart-disease (CHD) in connection with the consumption of alcohol and particularly of red wine. Inhibition of platelet aggregation by wine rather than an effect on atherosclerosis is presented as an explanation for protection from CHD in France. In CR5, Siemann and Creasy reported that the concentration of resveratrol in selected wines was determined as a function of variety, geographical origin, growing methods, and winemaking procedures. The results indicated that resveratrol might be the active ingredient in wines causing reduction of serum lipids. In CR6 and CR7, Frankel et al. reported that besides the alcohol content of wine, the phenolic compounds in red wine are assumed to have an important role in connection with the French paradox. The in-vitro studies show that the antioxidant properties of the phenolic substances in red wine inhibit the coppercatalyzed oxidation of human LDL. In CR8, Fitzpatrick et al. investigated possible effects of various grape wines and other grape products on vascular function in vitro. They remarked

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

that "[i]f such responses occur in vivo, they could ... contribute to a reduced incidence of coronary heart disease" (19). In CR9, Pace-Asciak et al. identified trans-resveratrol to be most important for the inhibition of platelet aggregation, thereby explaining the protective role of red wine against atherosclerosis and CHD. In CR10, Bertelli et al. examined the antiplatelet activity of synthetic and natural resveratrol in red wine. The results show that the antiaggregating effect of resveratrol is related to its concentration in red wine. In CR11, Jang et al. reported that resveratrol was found to have cancer preventive activity by acting as an antioxidant and antimutagen. The data suggest that resveratrol merits investigations as a potential cancer chemopreventive agent in humans. In CR12, Gehm et al. presented a study that broadens the spectrum of the biological actions of phenolic compounds in grapes and wines. They examined the estrogenic actions of resveratrol as a phytoestrogen in connection with human breast cancer cells. In CR13, Soleas et al. reviewed the literature about resveratrol. The authors of this review miss conclusive evidence for the absorption of resveratrol by humans in biologically significant amounts. They question but do not exclude beneficial activities as a consequence of moderate red wine consumption. In CR14, Fremont summarized the various biological effects of resveratrol isomers in connection with human cardiovascular diseases and cancer. It is suggested that the bioavailability and the metabolic pathways should be better known before drawing any conclusions on the benefits of resveratrol to health. In CR15, Manna et al. reported that the anti-cancerogenic and anti-inflammatory effects of resveratrol are partially ascribed by the inhibition of the activation of a nuclear transcription factor (NP-kappa B and AP-1) and associated kinases. In CR16, Hung et al. reported that resveratrol was found to be a potent antiarrhythmic agent with cardioprotective properties in rats, possibly correlated with its antioxidant activity and upregulation of NO production. In CR17, Wallerath et al. reported about the effect of resveratrol on nitric oxide synthase expression (eNOS) in human

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

endothelial cells. In conclusion, the stimulation of eNOS expression may contribute to the cardiovascular protective effects attributed to resveratrol. In CR18, Burns et al. examined the concentrations of resveratrol and its glycoside in grapes, peanuts, and Itadori tea, "which has long been used in Japan and China as a traditional herbal remedy heart disease and stroke" (20). The authors state that "for people who do not consume alcohol, Itadori tea may be a suitable substitute for red wine" (20). In CR19, Wang et al. demonstrated for the first time, that resveratrol can cross the blood-brain barrier and exert protective effects against cerebral ischemic injury. In CR20, Baur and Sinclair comprehensively and critically reviewed in vivo data on resveratrol and considered its potential as a therapeutic for humans. In CR21, Baur et al. discussed the improvement of health and survival of mice by resveratrol. The data "show that improving general health in mammals using small molecules is an attainable goal" (21). In CR22, Lagouge et al. revealed that resveratrol improves mitochondrial function and protects against metabolic disease in mice. In CR23, Brown et al. examined the cancer chemoprotective activity in healthy volunteers and analyzed the pharmacokinetic effects after repeated doses of resveratrol. "The results suggest that repeated administration of high doses of resveratrol generates micromolar concentrations of parent and much higher levels of glucuronide and sulfate conjugates in the plasma. The observed decrease in circulating IGF-I and IGFBP-3 might contribute to cancer chemopreventive activity." (22) In CR24, Cottart et al. reviewed the results of recent studies that investigated the pharmacokinetics, bioavailability, and toxicity of resveratrol in humans. As a result, resveratrol seems to be well tolerated with no marked toxicity, which provides further support for the use as a pharmacological drug in human medicine. In CR25, Pacholec et al. analyzed activation of SIRT1 by resveratrol and other structurally related compounds. The authors concluded that the tested compounds are not direct activators of SIRT1. In CR26, Patel et al. presented their study about the clinical pharmacology of resveratrol in colorectal cancer

patients. The results suggest that daily p.o. doses of resveratrol at 0.5 or 1.0 g elicit anticancerogenic effects. The authors stated that "resveratrol merits further clinical evaluation as a potential colorectal cancer chemopreventive agent" (23). In CR27, Chow et al. analyzed the effect of pharmacological doses of resveratrol on drug- and carcinogen-metabolizing enzymes of healthy volunteers. The authors concluded that resveratrol can modulate enzyme systems and thereby inhibit carcinogenesis. They suggest to consider lower doses of resveratrol for cancer prevention to minimize adverse metabolic drug interactions.

Table 2: Cited references that were cited very frequently in at least 15 different citing years (i.e.,

### N\_TOP10>=15) that are not included in Table 1

#CR	Cited Reference	RPY	NCR	N_TOP10
28	Subbaramaiah K., 1998, J. Biol. Chem., V273, P21875,	1998	216	17
	DOI 10.1074/jbc.273.34.21875			
29	Howitz K.T., 2003, Nature, V425, P191, DOI	2003	275	17
	10.1038/nature01960			
30	Clement M. V., 1998, Blood, V92, P996	1998	223	16
31	Goldberg D. A., 2003, Clin. Biochem., V36, P79, DOI	2003	156	16
	10.1016/S0009-9120(02)00397-1			
32	Walle T., 2004, Drug Metab. Dispos., V32, P1377, DOI	2004	259	16
	10.1124/dmd.104.000885			
33	Aggarwal B.B., 2004, Anticancer Res., V24, P2783	2004	202	16
34	Ray P.S., 1999, Free Radical Bio. Med., V27, P160, DOI	1999	158	15
	10.1016/S0891-5849(99)00063-5			
35	Bowers J.L., 2000, Endocrinology, V141, P3657, DOI	2000	114	15
	10.1210/en.141.10.3657			

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

36	Wu J.M., 2001, Int. J. Mol. Med., V8, P3	2001	105	15

In CR28, Subbaramaiah et al. report about the inhibition of specific biochemical pathways in human mammary and oral epithelial cells. The authors state that their "data are likely to be important for understanding the anti-cancer and anti-inflammatory properties of resveratrol." (24) In CR29, Howitz et al. found that resveratrol mimics caloric restriction of saccharomyces, resulting in increased DNA stability and extended lifespan of lower organisms. In CR30, Clement et al. reported on the anti-cancer activity of resveratrol by triggering the apoptosis in human tumor cells. The authors state that their data highlight the chemotherapeutic potential of resveratrol. In CR31, Goldberg et al. reported on the absorption of three wine-related polyphenols (trans-resveratrol, catechin, and quercetin) by healthy males, measuring the polyphenols in blood serum and urine after oral consumption. The absorption of trans-resveratrol was found to be the most efficient. In CR32, Walle et al. found high absorption but very low bioavailability of oral resveratrol in humans. However, they state that accumulation of resveratrol and its metabolites in epithelial cells may still cause cancer-preventive effects. In CR33, Aggarwal: et al. present an overview of preclinical and clinical studies dealing with the role of resveratrol in the prevention and therapy of cancer. In CR34, Ray et al. studied the potential cardioprotective effects of resveratrol using isolated rat hearts. The results indicate "that resveratrol possesses cardioprotective effects which may be attributed to its peroxyl radical scavenging activity." (25) In CR35, Bowers et al. reported on the biochemistry of resveratrol in connection with estrogen receptors, which seem to be important for the health effects of polyphenols. In CR36, Wu et al. reviewed the literature concerning the biosynthesis and presence of resveratrol in food groups and wines, the various reported health effects of resveratrol, and particularly the mechanism of its cardio-protective effect.

No additional cited references were found within the 15 most referenced cited references (NCR>=200). Therefore, we assume that we found the most impactful studies that are listed in Table 1 and Table 2.

## 4. Discussion and Conclusions

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

This bibliometric analysis deals with the health-related effects of resveratrol that occurs in wine and grapes. We employed the multidisciplinary database WoS due to the multidisciplinary nature of the topic. We analyzed the annual publication profile of the 3344 publications that were retrieved by our search query (see supporting information S1). Publication activity increased until 2010 and decreased slightly afterwards. We analyzed frequently occurring author keywords and classified them into six groups: (1) beveragesrelated keywords, (2) compounds-related keywords, (3) diseases-related keywords, (4) effects-related keywords, (5) mechanisms-related keywords, and (6) broader keywords. Finally, we analyzed and discussed the most frequently cited references (i.e., key papers) within the publication set. A comparatively large portion of the key papers revealed by the RPYS spectrogram and the N TOP10 indicator takes a positive attitude and reports about health effects of resveratrol. However, limited data in humans preclude drawing unambiguous conclusions on the healthrelated benefits of resveratrol. Conclusive evidence for resveratrol absorption by humans in biologically significant amounts and the mechanisms and metabolic pathways of the various potential health effects seem to be still lacking. In our analysis, we could not identify specific papers that imply a distinct change of direction of the ongoing scientific discourse. Moderate red wine consumption seems to have the potential of being health promoting, whereas excessive alcohol consumption can induce liver cirrhosis and cancer. Obviously, further

research and more in vivo studies are needed, before resveratrol (or red wine) becomes a pharmacological drug in human medicine.

Finally, we emphasize that we are no experts in the medical area and that more expert knowledge is needed for an in-depth interpretation of the results of our study. We presented a bibliometric method including the search query for retrieving the publication set and the appropriate analysis tools, i.e., VOSviewer and CRExplorer. Interested readers can study our RPYS results in more detail via the interactive RPYS spectrogram. Alternatively, readers with access to WoS can retrieve the relevant publications or modify the search query (if desired) and download the search results for further analysis according to their own interests and needs.

The more recent publications had hardly any chance to accumulate higher citation counts until present. Therefore, the explanatory power of RPYS steadily decreases towards the present. The differentiation between higher and lower impact papers diminishes and key papers can hardly be identified based on their citation impact.

#### References

- 357 Lucarini M, Durazzo A, Lombardi-Boccia G, Souto EB, Cecchini F, Santini A. Wine Polyphenols 1.
- 358 and Health: Quantitative Research Literature Analysis. Applied Sciences. 2021;11(11):4762.
- 359 Takaoka M. The Phenolic Substances of White Hellebore (Veratrum Grandiflorum Loes. Fill). 2.
- 360 V Synthesis of Resveratrol (3, 5, 4-Trioxystilbene) and its Derivatives. NIPPON KAGAKU KAISHI.
- 361 1940;61(10):1067-9.
- 362 Takaoka M. Resveratrol, a New Phenolic Compound, from Veratrum grandiflorum. Journal of
- 363 the Chemical Society of Japan. 1939;60(11):1090-100.
- 364 Wu JM, Wang ZR, Hsieh TC, Bruder JL, Zou JG, Huang YZ. Mechanism of cardioprotection by
- 365 resveratrol, a phenolic antioxidant present in red wine (Review). INTERNATIONAL JOURNAL OF
- 366 MOLECULAR MEDICINE. 2001;8(1):3-17.
- 367 Galton F. Vox Populi. Nature. 1907;75(1949):450-1. 5.
- Marx W, Bornmann L. Change of perspective: bibliometrics from the point of view of cited 368
- 369 references-a literature overview on approaches to the evaluation of cited references in bibliometrics.
- 370 Scientometrics. 2016;109(2):1397-415.
- 371 Bornmann L, Marx W. The wisdom of citing scientists. Journal of the American Society of 7.
- 372 Information Science and Technology. 2014;65(6):1288-92.
- 373 Birkle C, Pendlebury DA, Schnell J, Adams J. Web of Science as a data source for research on
- 374 scientific and scholarly activity. Quantitative Science Studies. 2020;1(1):363-76.
- 375 van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric
- 376 mapping. Scientometrics. 2010;84(2):523-38.
- Thor A, Bornmann L, Marx W, Mutz R. Identifying single influential publications in a research 377
- 378 field: new analysis opportunities of the CRExplorer. Scientometrics. 2018;116(1):591-608.
- 379 Thor A, Marx W, Leydesdorff L, Bornmann L. New features of CitedReferencesExplorer 11.
- 380 (CRExplorer). Scientometrics. 2016;109(3):2049-51.
- 381 Thor A, Marx W, Leydesdorff L, Bornmann L. Introducing CitedReferencesExplorer
- 382 (CRExplorer): A program for reference publication year spectroscopy with cited references
- 383 standardization. Journal of Informetrics. 2016;10(2):503-15.
- 384 R Core Team. R: A language and environment for statistical computing. 3.5.0 ed. Vienna, 13.
- 385 Austria: R Foundation for Statistical Computing; 2018.
- 386 Haunschild R. BibPlots: Plot functions for use in bibliometrics. R package version 0.0.8. 2021
- 387 [Available from: <a href="https://cran.r-project.org/web/packages/BibPlots/index.html">https://cran.r-project.org/web/packages/BibPlots/index.html</a>.
- 388 Vanderkam D, Allaire JJ, Owen J, Gromer D, Thieurmel B. dygraphs: Interface to 'Dygraphs'
- 389 interactive time series charting library. R package version 1.1.1.6. 2018 [Available from:
- 390 https://CRAN.R-project.org/package=dygraphs.
- 391 16. Tukey JW. Exploratory data analysis. Boston, MA, USA: Addison-Wesley Publishing Company;
- 392 1977.
- Thor A, Bornmann L, Haunschild R. CitedReferencesExplorer (CRExplorer) manual 2018 393 17.
- 394 [Available from: https://andreas-thor.github.io/cre/manual.pdf.
- 395 Haunschild R, Bornmann L. Reference Publication Year Spectroscopy (RPYS) in practice: Three
- 396 RPYS analyzes in the course of Workshop III "Cited References Analysis Using CRExplorer" at the 18th
- 397 ISSI conference2021 September 17, 2021. Available from: https://arxiv.org/abs/2109.00969.
- 398 Fitzpatrick DF, Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing activity of
- 399 wine and other grape products. American Journal of Physiology-Heart and Circulatory Physiology.
- 400 1993;265(2):H774-H8.
- 401 Burns J, Yokota T, Ashihara H, Lean MEJ, Crozier A. Plant Foods and Herbal Sources of
- 402 Resveratrol. Journal of Agricultural and Food Chemistry. 2002;50(11):3337-40.
- 403 Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves
- 404 health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337-42.

perpetuity.

It is made available under a CC-BY 4.0 International license .

- 405 22. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, et al. Repeat Dose Study
- 406 of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics,
- and Effect on the Insulin-like Growth Factor Axis. Cancer Research. 2010;70(22):9003.
- 408 23. Patel KR, Brown VA, Jones DJL, Britton RG, Hemingway D, Miller AS, et al. Clinical
- 409 Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients. Cancer Research.
- 410 2010;70(19):7392.

417

418

- 411 24. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, et al. Resveratrol
- 412 Inhibits Cyclooxygenase-2 Transcription and Activity in Phorbol Ester-treated Human Mammary
- 413 Epithelial Cells\*. Journal of Biological Chemistry. 1998;273(34):21875-82.
- 414 25. Ray PS, Maulik G, Cordis GA, Bertelli AAE, Bertelli A, Das DK. The red wine antioxidant
- resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radical Biology and
- 416 Medicine. 1999;27(1):160-9.

Supporting information S1 420 WoS search query 421 422 Supporting information S2 423 Author keyword replacements for grouping of clear synonyms 424




Figure 1




Figure 2

Five-year-median deviation

Figure 3